The opioid medication Opana ER is being voluntarily withdrawn from the market, its manufacturer Endo Pharmceuticals said in a statement Thursday. The decision comes less than a month after the U.S. Food and Drug Administration (FDA) requested that drug sales be halted, due to concerns over its potential for misuse and abuse.

On June 8, the FDA announced that an advisory committee had determined that Opana ER tablets—ER stands for extended-relief—had “dangerous unintended consequences” and that “the benefits of the drug may no longer outweigh the risks.” The FDA stated that if Endo did not voluntarily recall the drug, the agency would formally withdrawal approval. (Extended-relief opioids come with increased risks of addiction and overdose.)

At the time, Endo said it was reviewing the request and evaluating its options. Yesterday, the company released a statement saying that while it “continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER,” it has agreed to withdrawal the drug.

“Endo plans to work with FDA to coordinate the orderly removal of OPANA ER in a manner that looks to minimize treatment disruption for patients and allows patients sufficient time to seek guidance from their healthcare professionals,” the company’s statement reads. “Patients taking OPANA ER should discuss treatment options with their prescribing physician at their next visit.”

Get our Health Newsletter. Sign up to receive the latest health and science news, plus answers to wellness questions and expert tips. Please enter a valid email address. Sign Up Now Check the box if you do not wish to receive promotional offers via email from TIME. You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Thank you! For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Opana ER’s reported net sales for the first quarter of 2017 totaled $35.7 million, according to Endo’s statement, and the withdrawal will cost the company approximately $20 million. The statement also notes that “the Company has taken significant steps over the years to combat misuse and abuse,” and reiterates that its decision does not reflect any findings that the drug is not safe or effective when taken as prescribed.

Opioid addiction continues to be a serious problem across the U.S. A report released this week from the Centers for Disease Control and Prevention found that pain-relief prescriptions in the United States vary widely from county to county, with 6 times more opioids-per-resident in regions with the highest prescribing rate compared to the lowest. Counties in northern California, southern Nevada, and parts of Tennessee, Kentucky, and West Virginia had some of the highest per-capita rates.

Contact us at letters@time.com.